Adverum Biotechnologies Gross Profit

Adverum Biotechnologies posts a gross profit of $-12M as of September 2025. That compares with $-6.5M in the prior-year period — down 80.5% year over year. That is below the Healthcare sector average of $66B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Adverum Biotechnologies's gross profit was $-6.5M. The latest reading is $-12M — a 80.5% year-over-year decrease (period ending September 2025). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a gross profit near $66B is typical. Adverum Biotechnologies's $-12M is lower that level. That is roughly 100.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Gross Profit is one piece of Adverum Biotechnologies's financial statement story. At $-12M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for ADVM's gross profit usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $66B), and (3) consistency with growth and profitability. This page covers the first two; Adverum Biotechnologies's other metric pages and overview cover the third.